Patent application number | Description | Published |
20090081234 | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES FOR TREATMENT OF DEPRESSION AND RELATED CONDITIONS - The present invention relates to novel anti-TNF antibodies for use in the treatment of depression, including therapeutic compositions, methods and devices. | 03-26-2009 |
20090081241 | Anti-TNF Antibodies, Compositions, Methods and Uses - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 03-26-2009 |
20090252743 | Anti-TNF Antibodies, Compositions, Methods and Uses - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 10-08-2009 |
20090274707 | Anti-IL-12 Antibodies, Nucleic Acids Encoding Antibodies, and Methods of Production - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders. | 11-05-2009 |
20110082190 | Nucleic Acids Encoding Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders. | 04-07-2011 |
20120282170 | ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 11-08-2012 |
Patent application number | Description | Published |
20080213829 | Materials and methods to increase peptide chain expression - DNA sequences that increase peptide chain expression when operably linked to a gene encoding the peptide chain and methods of generating a peptide chain expression host cell using the foregoing are disclosed. Peptide chain expression host cells are also disclosed. | 09-04-2008 |
20080299133 | Anti-Il-12 Antibody Based Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 12-04-2008 |
20090202549 | Anti-IL-12 Antibodies, Epitopes, Compositions, Methods and Uses - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 08-13-2009 |
20090232734 | ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS - Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer. | 09-17-2009 |
20100216234 | Anti-IL-12 Antibody Based Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 08-26-2010 |
20110124024 | Proteolysis Resistant Antibody Preparations - Antibody preparations with substantially homogeneous and unsialylated glycoforms, such as G0 and G2, are prepared by enzymatic treatment, expression under certain conditions, use of particular host cells, and contact with serum. These antibody preparations resist cleavage by proteases, such as papain, ficin, bromolein, pepsin, a matrix metalloproteinase, such as MMP-7, neutrophil elastase (HNE), stromelysin (MMP-3) and macrophage elastase (MMP-12), and glycosylation modification enzymes. The antibody preparations with substantially homogeneous and unsialylated glycoforms and methods of testing for glycosylation in an antibody are useful in connection with characterization of antibody properties and/or in diseases or conditions characterized by an increase in protease activity. | 05-26-2011 |
20120207670 | Method for Treating Psoriasis by Administering An Anti-IL-12 Antibody - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis. | 08-16-2012 |
20140079628 | ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS - Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer. | 03-20-2014 |
Patent application number | Description | Published |
20080311034 | Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function - Variants of antibodies to human tissue factor are optimized for the capability to elicit effector functions produced by immune effector cells while maintaining the ability to neutralize the biological functions of tissue factor, such as the prevention of blood clotting via the extrinsic pathway, and are produced by mutations of the Fc-region of the antibody. The variants comprise A330Y, A330I, and I332E where the I332E variant may optionally further comprise a second substitution selected from A330I (in the case of the first substitution being I332E), V264I, and S239D. The variants may further be optimized for the capability to elicit effector functions produced by immune effector cells by production of the antibody variants under conditions that produce effector function enhancing glycosylation of the Fc-region. | 12-18-2008 |
20090214528 | HOST CELL LINES FOR PRODUCTION OF ANTIBODY CONSTANT REGION WITH ENHANCED EFFECTOR FUNCTION - Host cell lines for biopharmaceutical production of antibodies, antibody fragments or antibody-derived fusion proteins are selected as having the capability of inducing improved cellular effector functions, e.g., Fc-medicated effector functions. The host cells are derived from the rat myeloma cell line YB2/0 and are adapted to growth in chemically-defined medium. | 08-27-2009 |
20100172911 | Methods and Vectors for Generating Asialylated Immunoglobulins - The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity. | 07-08-2010 |
20120276092 | Antibody Glycosylation Variants - Antibody and other Fc-containing molecules with glycosylation variations in the Fc region show increased resistance to proteases, such as pepsin, plasmin, trypsin, chymotrypsin, a matrix metalloproteinase, a serine endopeptidase, and a cysteine protease. The Fc-containing molecules are useful in the treatment of various diseases and disorders. | 11-01-2012 |
20130064760 | Method for Treating Crohn's Disease By Administering An Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease. | 03-14-2013 |
20130129617 | Method for Treating Psoriatic Arthritis By Administering An Anti-IL-12 Antibody - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriatic arthritis. | 05-23-2013 |
Patent application number | Description | Published |
20140057319 | Methods and Vectors for Generating Asialylated Immunoglobulins - The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity. | 02-27-2014 |
20140141506 | Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 05-22-2014 |
20140161816 | ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 06-12-2014 |
20140178295 | Method for Treating Psoriasis By Administering An Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis. | 06-26-2014 |
20150030608 | Method of Treating Crohn's Disease By Administering An Anti-IL-12 Antibody - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 01-29-2015 |